TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Mediwound ( (MDWD) ).
On November 20, 2025, MediWound Ltd. announced its third-quarter financial results, highlighting a 23% year-over-year revenue increase to $5.4 million. The company completed the commissioning of its expanded NexoBrid manufacturing facility, expected to reach full operational capacity by the end of 2025, significantly boosting production to meet global demand. The ongoing VALUE Phase III trial of EscharEx is progressing well, with a peak sales opportunity estimated at $831 million. MediWound also strengthened its balance sheet with $30 million in equity financing, supporting its development and commercialization efforts.
The most recent analyst rating on (MDWD) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score reflects significant challenges in financial performance, particularly in profitability and cash flow management. However, the company shows potential for growth through strategic partnerships and clinical advancements. Technical indicators suggest a neutral trend with potential for upward movement. The earnings call provided positive guidance and strategic focus, but ongoing financial losses and valuation concerns weigh on the overall score.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on tissue repair. The company operates in the healthcare industry, primarily offering products like EscharEx® for venous leg ulcers and NexoBrid® for burn treatment. MediWound is committed to advancing its late-stage clinical programs and expanding its market presence globally.
Average Trading Volume: 94,262
Technical Sentiment Signal: Buy
Current Market Cap: $229M
For an in-depth examination of MDWD stock, go to TipRanks’ Overview page.